In this week’s episode we’ll speak with Rocco De Bernardis, Global President of OTTAVA, Johnson & Johnson MedTech. This week, J&J MedTech announced it was filing an IDE to begin clinical trials on its surgical robotics system, Ottava, in 2024. But what does this mean? What does Ottava look like? Why does J&J MedTech think it has what it takes to win over surgeons? And what does the future look like for the company’s surgical robotics platform?

Co-hosts Tom Salemi and Chris Newmarker also chat with Karthik Bolisetty, senior associate at VC firm Gilde Healthcare, about the impact GLP-1 drugs could have on medical device start-ups. How does Gilde see the weight loss drugs impacting its portfolio and future investments?

Finally, Gregg Tobin, CEO of Aptyx, our episode sponsor, talks about how the company’s new name better reflects its capabilities. Go to Aptyx.com for more information.

Thanks for listening to the DeviceTalks Weekly podcast.

Subscribe to the DeviceTalks Podcast Network on any major podcast application.

Hear Why J&J Medtech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of GLP-1 drugs

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Hear Why J&J Medtech Is Ready to Move Forward with Ottava; A VC Discusses the Impact of GLP-1 drugs

DeviceTalks

Related tracks